Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

Finasteride and minoxidil can revive hair dormant for up to 7 years, with microneedling enhancing regrowth. Users report significant hair regrowth even after long periods of baldness.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

Bee venom at 0.001% concentration was more effective than 2% minoxidil in promoting hair growth in mice, possibly due to increased growth factors and reduced inflammation. Caution is advised due to potential allergic reactions and the reliance on animal data.

Combining finasteride and dutasteride may enhance hair regrowth by targeting different enzymes, with positive results reported. Minoxidil, both oral and topical, is also used to improve effectiveness.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.

Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.

Hair loss is reportedly starting earlier in younger generations, with potential causes including prediabetes and decreased dietary minerals and vitamins. Minoxidil is mentioned as a treatment that supports capillary health and promotes hair growth.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

Some users report eye issues like blurry vision and dry eyes while using finasteride or dutasteride, though others experience no changes. Concerns about myopia progression are discussed, but no clear link to these medications is established.

Androsterone may help with sexual and affective dysfunction from finasteride by replacing disrupted neurosteroids without increasing androgenic side effects. Controlled testing is needed to confirm its effectiveness and safety.

Dutasteride is effective for hair loss but may cause side effects like decreased sperm count, which might not fully recover after stopping. Users discuss balancing dosages to minimize side effects while maintaining benefits.

Dutasteride studies for hair loss are often sponsored by GlaxoSmithKline, raising concerns about potential bias. Despite this, some users report positive results with dutasteride and oral minoxidil, while others remain skeptical of industry-funded research.

Dutasteride is shown to be significantly more effective than finasteride for treating male androgenic alopecia. Users discuss the difficulty of obtaining dutasteride in some countries and share personal experiences with its effectiveness and side effects.

Using a combination of low-dose oral and topical finasteride, along with minoxidil, may effectively manage hair loss by targeting both systemic and local DHT. Users report positive experiences with this regimen, noting good tolerability and no worsening of hair condition.

Microneedling can be effective for hair growth, but it is more effective when combined with minoxidil. Finasteride or other DHT suppressants are necessary to prevent hair loss due to male pattern baldness.

A 30-year-old male experienced significant hair regrowth after five months of using topical minoxidil (5% foam) and oral dutasteride (0.5 mg daily). The user reported no side effects and was grateful for the progress, despite the rapid gains slowing down.

Nizoral shampoo effectively reduces scalp itchiness and dandruff, particularly for those using minoxidil, and may promote hair growth despite not being FDA-approved for this purpose. Users report significant improvements in scalp health and reduced itchiness with regular use.

Dutasteride significantly reduces scalp DHT levels and can save hair, though shedding is part of the process. Some users report success with dutasteride, while others struggle despite using it along with finasteride and oral minoxidil.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

The post discusses the difference in effects of Minoxidil (Min) on scalp and facial hair. The user questions why Min-induced hair growth on the scalp is temporary, while facial hair growth seems permanent, even after stopping Min. They propose theories, including different Min mechanisms on body and facial hair, the role of DHT, and the possibility of not achieving fully terminal hair. The responses include personal experiences and theories about Min's effects on hair growth.

Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.

RU58841 is considered ineffective as a standalone treatment for hair loss, with users often combining it with finasteride and minoxidil for potential benefits. Many users report mixed results and concerns about side effects, leading to skepticism about its efficacy.

Many users have maintained their hair using finasteride, with some also using minoxidil or dutasteride, reporting minimal side effects. Opinions vary on the necessity of DHT, with some users arguing its importance beyond puberty, while others believe it is unnecessary and that finasteride and dutasteride are safe and effective for hair maintenance.

The conversation discusses concerns about getting a hair transplant with the potential release of a new treatment, PP405, which may regrow dormant hair follicles. The user is currently using Minoxidil, Derma, and Keto but is waiting to start finasteride or dutasteride.

Topical pirfenidone is highlighted as an effective anti-inflammatory and anti-fibrotic treatment for hair loss, particularly in addressing perifollicular fibrosis, which may enhance the effectiveness of standard treatments like finasteride and minoxidil. The user also uses calcipotriol, MCT oil, ciclopirox shampoo, and benzoyl peroxide shampoo as part of their regimen.

Finasteride and minoxidil are commonly used for hair loss, with RU58841 and microneedling also showing effectiveness. Oral minoxidil and dutasteride are noted for their impact, while side effects and alternative treatments like ketoconazole and natural DHT blockers are discussed.